Your browser doesn't support javascript.
loading
Development of ligand modified erythrocyte coated polydopamine nanomedicine to codeliver chemotherapeutic agent and oxygen for chemo-photothermal synergistic cancer therapy.
Zhang, Liyao; Huang, Peijie; Huang, Shubin; Wang, Tao; Chen, Shufeng; Chen, Zhihao; Zhou, Yi; Qin, Linghao.
Afiliación
  • Zhang L; School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou 510006, PR China.
  • Huang P; School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou 510006, PR China.
  • Huang S; School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou 510006, PR China.
  • Wang T; Department of Pharmacy, Changzhi Medical College, Changzhi 046000, PR China.
  • Chen S; School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou 510006, PR China.
  • Chen Z; School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou 510006, PR China.
  • Zhou Y; School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou 511436, PR China. Electronic address: zhouyi0264@126.com.
  • Qin L; School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou 510006, PR China; Guangdong Provincial Key Laboratory of Advanced Drug Delivery Systems, Guangdong Pharmaceutical University, Guangzhou 510006, PR China. Electronic address: qins_lab@163.com.
Int J Pharm ; 626: 122156, 2022 Oct 15.
Article en En | MEDLINE | ID: mdl-36058410
The use of conventional chemotherapy often faces limitations such as severe side effects, weak tumor tissue specificity, and the development of multidrug resistance. To conquer these challenges, numerous novel drug carriers have been designed in recent years. However, due to the complex processes of tumor development, metastasis and recurrence, single chemotherapy cannot fulfill the goals of clinical diverse treatment. In this work, by utilizing the inherent characteristics of surface-modified erythrocyte and the outstanding photothermal conversion capability of polydopamine (PDA), we designed and constructed a biomimetic multifunctional nanomedicine DPPR NPs to codeliver chemotherapeutic agent doxorubicin (DOX) and oxygen. The results showed that DPPR NPs exhibited inspiring features including nanoscale droplet size, good physicochemical stability, and sustained, pH-, and NIR triggered drug release behavior. It can dramatically prolong the systematic circulation time and elevated the drug accumulated level in the tumor site. Moreover, DPPR NPs could be effectively internalized into tumor cells and destroyed the intracellular redox balance to mediate cell apoptosis. It exerted excellent in vivo tumor targeting effect, photothermal conversion efficiency, ultrasound imaging responses, antitumor efficacy, and good compatibility. In summary, DPPR NPs provide a biomimetic drug delivery platform to organically combine chemotherapy and photothermal therapy for precise cancer treatment.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Nanopartículas / Hipertermia Inducida / Neoplasias / Antineoplásicos Límite: Humans Idioma: En Revista: Int J Pharm Año: 2022 Tipo del documento: Article Pais de publicación: Países Bajos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Nanopartículas / Hipertermia Inducida / Neoplasias / Antineoplásicos Límite: Humans Idioma: En Revista: Int J Pharm Año: 2022 Tipo del documento: Article Pais de publicación: Países Bajos